Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The 2 faces of ERK2 in MPNs.

Journal article

Havelange V. and Constantinescu SN., (2022), Blood, 140, 298 - 300

Studying severe long COVID to understand post-infectious disorders beyond COVID-19.

Journal article

Brodin P. et al, (2022), Nature medicine, 28, 879 - 882

JAK inhibitors and COVID-19.

Journal article

Levy G. et al, (2022), Journal for immunotherapy of cancer, 10

Degrading JAK2 in ALL by ruxolitinib-based PROTACs

Journal article

Constantinescu SN. and Pecquet C., (2021), Blood, 138, 2301 - 2302

MPL S505C enhances driver mutations at W515 in essential thrombocythemia.

Journal article

Varghese LN. et al, (2021), Blood cancer journal, 11

Pituitary incidentaloma.

Journal article

Constantinescu SM. and Maiter D., (2021), Presse medicale (Paris, France : 1983)

Functional Consequences of Mutations in Myeloproliferative Neoplasms

Journal article

Constantinescu SN. et al, (2021), HemaSphere